SLC5A2 and diabetes mellitus: These findings warrant future randomized controlled trials to confirm the cardioprotective effects of SGLT2 inhibitors in cancer patients with and without diabetes and to evaluate their safety and efficacy in specific cancer types and treatment regimens.